Hereditary Angioedema (HAE) National Surveillance Project
VOORHEES, N.J., Oct. 22 -- Hereditary angioedema (HAE) is an autosomal dominant disease estimated to afflict between 1 in 10,000 to 1 in 50,000 people in the United States. Patients with HAE suffer from recurrent attacks of intense localized edema involving the skin, airway, extremities, and visceral organs. Management of HAE may involve short-term treatment and long-term prophylaxis. There are currently several new treatments under investigation for both prophylaxis and acute attacks of HAE.
To assess the current state of care in the United States for HAE patients, Robert Michael Educational Institute LLC (RMEI) is conducting an online survey of healthcare professionals who treat patients with HAE. The data submitted by participants will provide insights that may lead to advancements in the management of this disease.
Healthcare professionals can visit www.RMEI.com/HAEproject to participate in the survey. The first 500 healthcare professionals to complete this survey will receive a $25 Visa gift card. This activity is supported by an educational grant from ViroPharma Incorporated.
RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment, leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.
For other educational opportunities, please visit www.RMEI.com.
SOURCE Robert Michael Educational Institute LLC